Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • infectious diseases

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    - PMLiVE

    Sanofi reports improved patient outcomes from high-dose influenza vaccine

    Study data shows a reduced risk of hospitalisation in older adults compared with standard-dose vaccines

    - PMLiVE

    A Call to Action: Bridging the Adult Immunization Divide

    Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

    Medscape Education

    - PMLiVE

    Sanofi appoints Lisa Sha as general manager, vaccines in the UK & Ireland

    Sha joined Sanofi in 2019 and takes up her new role with immediate effect

    - PMLiVE

    Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

    More than 180,000 people worldwide are diagnosed with the disease every year

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

    The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

    - PMLiVE

    Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

    The deal includes an early-stage combination vaccine candidate for RSV and hMPV

    - PMLiVE

    Sanofi’s Sarclisa recommended by CHMP for new multiple myeloma indication

    Around 46,000 cases of the disease are expected to be diagnosed in Europe this year

    - PMLiVE

    Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

    Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

    - PMLiVE

    Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

    These are the first clinical study results for the drug in a large population of patients with darker skin tones

    - PMLiVE

    Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

    The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links